| Name | Piracetam |
| Description | Piracetam (UCB-6215), a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), is used in therapy of the extensive cognitive disorders. |
| In vitro | Excluding the cerebellum, Piracetam enhances active avoidance learning in aged rats and increases membrane fluidity across all brain regions. A daily dose of 300 mg/kg Piracetam significantly boosts membrane fluidity in certain cerebral areas of aged rats without noticeable effects on juvenile rats. Six weeks of daily administration of 300 mg/kg Piracetam elevates NMDA receptor density in the hippocampus, as well as the density of muscarinic cholinergic receptors in the frontal cortex and striatum, with a slight increase also observed in the hippocampal region. Oral administration of 500 mg/kg Piracetam for 14 consecutive days increases NMDA receptor density by approximately 20% in aged mice and restores the normal affinity of L-glutamate for NMDA receptors. Compared to control and alcohol-fed rats, those treated with Piracetam show a 20% increase in synaptic numbers, suggesting a mechanism of synaptic reorganization at the level of mossy fiber synapses. |
| In vivo | Piracetam, when pre-incubated with lipopolysaccharides (at Piracetam to peptide ratios ranging from 9.6 to 960), can dose-dependently inhibit the peptide-induced release of calcein completely. It has been observed through the reduced anisotropy of the membrane-bound fluorescent probe 1,6-diphenyl-1,3,5-hexatriene (DPH) that Piracetam (< 1.0 mM) can enhance the membrane fluidity of brain cells in aged rats, mice, and humans. Piracetam significantly reduces the fusion and destabilizing effects of Abeta 29-42 in a concentration-dependent manner. Pre-incubating Piracetam with the peptide at a 960 ratio, 20 minutes before introducing Abeta 29-42, fully protected both types of fluorescent probes. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (351.72 mM), Sonication is recommended.
H2O : 351.72 mM, Sonication is recommended.
|
| Keywords | UCB6215 | UCB 6215 | Piracetam | Ionotropic glutamate receptors | Inhibitor | inhibit | iGluR | AMPA |
| Inhibitors Related | Mephenesin | Urethane | L-Glutamic acid | L-Phenylalanine | glycine | Evans blue | L-Glutamine | Direct Blue 1 | L-Glutamic acid monosodium salt | D-Cycloserine | Linalool | O-Phospho-L-serine |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
